Trials such as TOPCAT and PARAGON-HF failed to meet hospitalization reduction primary endpoints in patients with HFpEF.(5,6) However, the EMPEROR-Preserved and DELIVER trials led the ACC/AHA/HFSA to recommend the sodium glucose-cotransporter 2 (SGLT2) inhibitors, empagliflozin and dapagliflozin, for hospitalization reduction in HFpEF.(7-9) Semaglutides Role in HFpEF Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, and slows gastric emptying.(10) GLP-1 RAs, including liraglutide, dulaglutide, and semaglutide significantly improve glycemic control, promote weight loss, and reduce atherosclerotic cardiovascular and renal risk.(11) Among the approved GLP-1 RAs in the United States, semaglutide and tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA, have emerged as possible therapies for patients with HFpEF.(12-14) These agents may improve physical function and enhance quality of life by reducing adiposity, leptin levels, and RAAS activation

Monitor for new or worsening depression and mood changes
Op de lange termijn kan dit ook bijdragen aan leververvetting (NAFLD), een aandoening waarbij vet ophoopt in de lever en de leverfunctie kan verslechteren
It is created from glucose and lauryl alcohol